Show Me the Data: Translating Clinical and Practice-Based Evidence on Oral SERDs Into Everyday Care for HR+/HER2– Metastatic Breast Cancer

Highlights from the PER® CME activity "Show Me the Data: Translating Clinical and Practice-Based Evidence on Oral SERDs Into Everyday Care for HR+/HER2– Metastatic Breast Cancer" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts Reshma L. Mahtani, DO; Kamel Abou Hussein, MD; and Irene Kang, MD; discuss how to translate clinical and real-world evidence regarding oral selective estrogen receptor degraders (SERDs) and targeted combination therapies into everyday clinical practice for managing hormone receptor–positive/HER2-negative metastatic breast cancer.

Earn CME credit by completing the full accredited activity (available through April 21, 2027):
https://www.gotoper.com/courses/show-me-the-data-translating-clinical-and-practice-based-evidence-on-oral-serds-into-everyday-care-for-hrher2-metastatic-breast-cancer-zeds">https://www.gotoper.com/courses/show-me-the-data-translating-clinical-and-practice-based-evidence-on-oral-serds-into-everyday-care-for-hrher2-metastatic-breast-cancer-zeds

This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from Stemline Therapeutics, Inc.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.